TY - JOUR T1 - Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience. AU - Siersma,Carolien, AU - Brouwer,Carole N M, AU - Sojak,Vladimir, AU - Ten Harkel,Arend D J, AU - Roeleveld,Peter P, PY - 2022/10/27/entrez PY - 2022/10/28/pubmed PY - 2022/10/29/medline KW - aortic operation KW - coarctation KW - congenital heart surgery KW - database KW - intensive care KW - pediatric SP - 701 EP - 706 JF - World journal for pediatric & congenital heart surgery JO - World J Pediatr Congenit Heart Surg VL - 13 IS - 6 N2 - BACKGROUND: Although considering the pathophysiology of post-coarctectomy hypertension, β-blockers should be effective, experience with labetalol for treatment is limited in the literature. METHODS: Retrospective collection and analysis of data in children aged ≤6 years following coarctectomy in our tertiary care university medical center between January 2009 and June 2018. RESULTS: 96 patients were included, 45 were treated with intravenous labetalol and 51 received no treatment. Median time to maximum dose received (median 1.1 mg/kg/h) was 2.7 h, and median time to the reduction of labetalol dose was 8.3 h. No antihypertensives had to be added. In one child, labetalol was switched to nitroprusside due to bronchoconstriction. Of patients receiving intravenous labetalol, 48% had been switched to oral labetalol at discharge. CONCLUSIONS: Intravenous labetalol is a fast, effective, and safe drug to treat hypertension following aortic coarctation repair. Labetalol is easily converted to oral therapy when the continuation of treatment is considered necessary. SN - 2150-136X UR - https://www.unboundmedicine.com/medline/citation/36300272/Treatment_of_Post-Coarctectomy_Hypertension_With_Labetalol-A_9-Year_Single-Center_Experience. DB - PRIME DP - Unbound Medicine ER -